Trials · Topics · Hematologic Malignancies
Hematologic Malignancies clinical trials
26 Hematologic Malignancies trials (Medical Oncology and Radiation Oncology) summarized for fellows and board review, newest first within each disease. Each summary covers design, results, toxicity and what changed in practice.
Jump to: HL · DLBCL · MM · MZL/MALT · Practice guidelines · FL · PCNSL · T/NK-cell
HL (8)
- EORTC H10 5-Year Update (Andre) JCO 2017Mature 5-yr data confirm PET-guided RT omission in PET-negative early favorable HL yields significantly inferior PFS vs CMT, with no OS benefit from omitting RT....
- GHSG HD10 Long-Term Update (Sasse) JCO 2017The non-inferiority of 2 cycles ABVD + 20 Gy IFRT is maintained at long-term (11-year) follow-up with equivalent OS and second malignancy rates, confirming this as...
- UK RAPID N Engl J Med 2015In PET-negative early-stage HL after 3 cycles ABVD, RT omission results in a small (3.8%) absolute reduction in 3-year PFS but non-inferiority was met only in...
- EORTC H10-F and H10-U JCO 2014RT omission in PET-negative early-stage Hodgkin lymphoma yields significantly inferior PFS vs standard CMT (ABVD + involved-node RT), even when interim PET is...
- GHSG HD10 N Engl J Med 20102 cycles of ABVD + 20 Gy IFRT is non-inferior to 4 cycles + 30 Gy for early favorable Hodgkin lymphoma with significantly less acute toxicity. This regimen became the...
- EORTC H8-F and H8-U N Engl J Med 2007CMT (MOPP/ABV + IFRT) achieves superior or equivalent EFS vs STNI alone with reduced radiation fields. IFRT-based CMT replaced STNI as the standard for early-stage...
- GHSG HD7 JCO 2007Adding 2 cycles of ABVD to extended-field RT dramatically improved freedom from treatment failure (88% vs 67%) in early favorable Hodgkin lymphoma, confirming CMT...
- GHSG HD4 JCO 2001Combined modality therapy with 2 cycles COPP/ABVD + IFRT significantly improved freedom from treatment failure compared with extended-field RT alone for early...
DLBCL (6)
- RT in Non-Bulky Limited Stage DLBCL (Lamy) Blood 2018In non-bulky limited-stage DLBCL achieving CMR after R-CHOP, consolidation RT does not improve EFS or OS and can be safely omitted. PET-guided response assessment...
- SEER Limited Stage DLBCL RT Analysis (Odejide) Leuk Lymphoma 2015Real-world SEER-Medicare data suggest that consolidation RT is associated with improved lymphoma-specific survival for limited-stage DLBCL in the rituximab era...
- RICOVER-noRTh (DLBCL Consolidation RT) JCO 2014Conclusion: Omitting RT in bulky/extranodal DLBCL significantly worsens PFS Conclusions: Omitting consolidation RT in elderly DLBCL patients with bulky (≥7.5 cm) or...
- IELSG-10 Primary Testicular DLBCL (Vitolo) JCO 2011R-CHOP + intrathecal MTX + contralateral testicular RT achieves 5-yr OS of 85% in PT-DLBCL. Contralateral testicular RT eliminates the characteristic relapse pattern...
- MDACC R-CHOP + RT Limited Stage DLBCL (Phan) JCO 2010CMT with R-CHOP + IFRT achieves excellent outcomes for limited-stage DLBCL in the rituximab era, with 5-yr OS of 91%. Local recurrence is rare with consolidation...
- ECOG 1484 (DLBCL Consolidation RT) JCO 2004Consolidation IFRT after CR with CHOP improved DFS but not OS in limited-stage aggressive NHL in the pre-rituximab era. The DFS benefit reflects improved local tumor...
MM (5)
- Düsseldorf Multiple Myeloma RT (Matuschek) Radiat Oncol 2015RT is highly effective for pain control in MM bone lesions, achieving an 85% overall response rate. Higher RT doses (>30 Gy) are associated with improved pain relief...
- MDACC Solitary Plasmacytoma (Reed) Cancer 2011Definitive RT achieves excellent local control (92%) in solitary plasmacytoma. Progression to MM remains the dominant long-term problem, occurring in ~47% at 5 years...
- Multicenter SP Rare Cancer Network (Ozsahin) Int J Radiat Oncol Biol Phys 2006RT achieves 86% 5-year local control in solitary plasmacytoma. Progression to MM (45% at 5 years) is the main long-term failure mode. No dose-response relationship...
- Spinal Cord Compression in Multiple Myeloma (Rades) Int J Radiat Oncol Biol Phys 2006Long-course RT significantly improves motor function compared to short-course at both 6 and 12 months in myeloma-related SCC. For patients with reasonable performance...
- Extramedullary Plasmacytoma (Alexiou) Cancer 1999EMP is radiosensitive and has a favorable prognosis compared to bone SP, with low rates of progression to MM (~11-15%). RT alone achieves excellent local control for...
MZL/MALT (2)
- IELSG Orbital MALT Lymphoma (Wirth) Ann Oncol 2013Involved-field RT to 24-26 Gy achieves excellent local control for localized orbital MALT lymphoma, with ~75-80% disease-free survival at 5 years. Distant failure...
- MSKCC Gastric MALT Experience (Schechter) JCO 1998Involved-field radiotherapy achieves excellent local control and durable complete remission in H. pylori-negative or treatment-refractory gastric MALT lymphoma. RT to...
Practice guidelines (2)
- ILROG Follicular Lymphoma RT Guidelines (Brady) Blood 2019RT remains a standard curative option for stage I-II FL, with ~50% of patients achieving durable remission with RT alone. Two-fraction palliative RT (4 Gy) is an...
- ILROG Multiple Myeloma RT Guidelines (Tsang) Int J Radiat Oncol Biol Phys 2018ILROG guidelines provide consensus dose recommendations across the spectrum of myeloma presentations. RT remains highly effective for local control in SPB and EMP...
FL (1)
- FoRT (Follicular Lymphoma Radiotherapy) Int J Radiat Oncol Biol Phys 2012Both 4 Gy and 24 Gy achieve useful palliation for symptomatic indolent NHL lesions. 24 Gy provides significantly better local control and higher complete response...
PCNSL (1)
- RTOG 9310 (Primary CNS Lymphoma) JCO 2002MTX-based induction followed by WBRT achieves significantly better OS compared with WBRT alone for PCNSL. However, delayed neurotoxicity is severe in patients >60...
T/NK-cell (1)
- Korea NK/T-Cell Lymphoma CCRT (Kim) JCO 2009CCRT achieves significantly higher CR rates and improved OS compared with CHOP-based chemotherapy alone or sequential approaches for stage I-II NK/T-cell lymphoma....